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Background: Metastasis have considered as an important clinical obstacle in the treatment of human cancer
including bladder cancer. Post-transcriptional regulation has emerged as robust effectors of metastasis. MiRNAs are
involved in cancer development and progression, acting as tumor suppressors or oncogenes. In this study, we focus
on it that microRNA-34a functions as an anti-metastatic microRNA and suppress angiogenesis in bladder cancer by
directly targeting CD44.
Methods: The expression of mir-34a was detected by quantitative real-time PCR. Oligonucleotide and lentivirus
were used to overexpress miR-34a. Tube formation assay and transwell assay were used to examine the effect on
bladder cancer tube formation, migration and invasion in vitro. Animal models were used to examine the effect on
metastasis and angiogenesis in vivo. Luciferase assay was carried out to verify the precise target of miR-34a.
Results: We not only proved that mir-34a was significantly downregulated in bladder cancer tissues and cell lines
but also that circulating miR-34a levels are reduced in bladder cancer, and their levels were positively relevance.
Gain-of-function experiments investigated that increased mir-34a expression suppressed tube formation and
reduced cell migration and invasion. In vivo metastasis, assays also demonstrated that overexpression of mir34a
markedly inhibited bladder cancer metastasis. CD31, an endothelial cell–specific marker which stained in T24 tumors
to evaluate for blood vessel density, the immunohistochemistry results showed that blood vessel quantification
reduced dramatically in the T24 tumors over-expressing mir-34a. Combining with our previous studies and
bioinformatics analysis, we expected that CD44 gene was a direct target of mir-34a, siRNA-mediated knockdown of
CD44 partially phenocopied mir-34a overexpression suggesting that the pro-apoptotic role of mir-34a may be
mediated primarily through CD44 regulation, whereas restoring the expression of CD44 attenuated the function of
mir-34a in bladder cancer cells. Additionally, we identified that EMT (epithelial-mesenchymal transition) related
proteins could be regulated by mir-34a which indicated that mir-34a could partially reserve EMT.
Conclusion: Our study defines a major metastasis and angiogenesis suppressive role for mir-34a, a microRNA functions
as a tumor suppressor in bladder cancer by directly targeting CD44, which would be helpful as a therapeutic approach
to block bladder cancer metastasis.
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Bladder cancer is the most common urinary tract malig-
nancy and the fifth most common malignancy in the de-
veloped world and is the most common urological
tumor in China. This kind of urinary cancer is also with
a complicated, multifactorial etiology, involved with both
genetic and environmental factors. Besides, the disease is
characterized by frequent recurrences and poor clinical
outcome when tumors progress to invasive disease. At
diagnosis, the most prevalent histopathologic type of
bladder cancer in Western countries is transitional cell
carcinoma (TCC) accounting for up to 95% of all cases.
Approximately 70% of bladder cancer presents with
non-muscle invasive bladder cancer tumors, while the
remaining cases have invasive tumors [1]. For the pa-
tients with non-muscle invasive tumors, they should
often be treated by transurethral resection, and with up
to 70% of these cases developing at least one recurrence
within 5 years [2]. Because of the characters of this dis-
ease, early diagnosis and evolution has become very im-
portant. Up to now, many studies have investigated
molecular biomarkers for prediction of risk and recur-
rence of bladder cancer. Although some positive results
have been obtained and successfully replicated in our
previous studies [3-6], they could not explain all the por-
tions of the pathogenesis of bladder cancer and did not
put forward the feasible treatment scheme, so the bio-
logical theory of bladder cancer need further research.
MicroRNAs are single strand, noncoding RNA mole-
cules that normally functions as negative regulators of
mRNA expression of the target genes at the posttran-
scriptional level [7], through specific targeting of multi-
cellular eukaryotic miR3-UTRs miRs down-regulate
gene expression by inducing the degradation or impair-
ing the translation of target mRNAs [8]. Previous accu-
mulated evidence has shown that biological processes
such as angiogenic signaling, organ development, cell
proliferation, apoptosis avoidance, EMT and tumor inva-
sion pathways are regulated by different microRNAs
[9-11]. The current estimate is that >90% of human
genes could be controlled by the microRNAs [8]. De-
regulation of miRNA expression has been identified in
many kinds of human cancer including bladder cancer,
and much proved evidences have indicated that some
special microRNAs could be functioned as oncogenes or
tumor suppressor genes. This crucial findings support us
with new strategies in treating human cancer by inacti-
vating oncogenic microRNAs or restoring tumor sup-
pressor microRNAs [12,13]. Furthermore, the first
report of altered miRNA expression in bladder cancer
appeared in 2007 and detected upregulation of 10 miR-
NAs [14] and urinary miRNAs have been shown to be
clinically useful for noninvasive bladder cancer diagnos-
tics [15]. Recently, it’s reported that miR-19a could actas an oncogenic microRNA in bladder cancer by target-
ing PTEN when miR-320c could inhibit tumorous be-
haviors of bladder cancer by targeting CDK6 and both
of them could be potential biomarkers of bladder cancer
[16,17]. Otherwise, circulating miRNAs have potential
use as predictive biomarkers for diagnosis and prognosis
of cancer [18]. However, most work has focused on tis-
sue and cell expression with few reports of circulating
miRNAs in bladder cancer. Available biomarkers for
bladder cancer have limited sensitivity and specificity,
and with the urgent treatment in bladder cancer, new
markers are needed. Owing to miRNAs’ ubiquity and
the characters described above, they also constitute a
promising class of biomarkers tailored for human cancer
detection, diagnosis, assessment of prognosis, and pre-
diction of response to therapy. Moreover, due to their
dynamic and reversible properties, those alterations rep-
resent a target for miRNAs-directed therapies.
MiR-34a has been described as a “star” miRNA in can-
cer research, which commonly functions as a tumor sup-
pressor and is down-regulated in many human cancers
[19], Furthermore, the aberrant miR-34a expression has
been linked to chemotherapy resistance in a variety of
cancer [20-25]. On the other hand, miR-34a is up-
regulated in some specific type of cancer, such as papil-
lary thyroid carcinoma (PTC) [26]. Abnormal prolifera-
tion and apoptosis are main characters of cancer cells.
In PCT, miR-34a promotes proliferation and suppresses
apoptosis by targeting Growth arrest specific1 (GAS1),
which can suppressor that inhibits cancer cell prolifera-
tion and induces apoptosis through inhibition of RET re-
ceptor tyrosine kinase, via PI3K/Akt/Bad pathway [26].
However, despite the fact that more and more evidences
indicated mir-34a plays a crucial role in the biology pro-
cesses of bladder cancer, the role of mir-34a in the de-
velopment and progression remains elucidated in
bladder cancer. A better understanding of the role of
miR-34a as a potential therapeutic target in bladder gen-
etic analyses suggested that bladder is a genetic disease
involving multiple types of gene changes, including miR-
NAs by the recent decades of research [27,28]. CD44 is
a surface adhesion molecule and it has been identified as
the prostate cancer and cystic cancer stem cell marker
[29,30], and emerged as an important gene in multiple
aspects of cancer development [31] and progression
[32-34]. The analysis of CD44 isoforms in invasive bladder
cancer cells CD44 is largely divided into CD44 standard
isoform and variant isoforms, exclusively expressed in
mesenchymal cells and epithelial cells, respectively
[35-37]. Besides that, CD44v6 could interact with c-Met,
thereby enabling cancer cells to be susceptible for growth
factor microenvironment, in parallel with EpCAM expres-
sion [38]. In fact, the relationship between mir-34a and
CD44 may have more connotations. Mutation of p53 can
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certain critical features of malignancy, including metabolic
reprogramming known as Warburg effect [39]. It was re-
ported that p53 had a miR-34a-dependent integrated
mechanism to regulate glucose metabolism [39]. Aberrant
miR-34a expression has been linked to chemotherapy
resistance in a variety of cancer. CD44v8-10 can protect
cancer cells from redox stress and up-regulation of
CD44v8-10 after chemotherapy has been reported in Li-
Fraumeni syndrome (LFS) associated simultaneous osteo-
sarcoma and liver cancer, which is p53-deficinet [40,41].
EMT alters CD44 splicing pattern, in which CD44v is re-
placed by CD44s. It has also been reported that increased
invasion capacity to be due to increased Akt signal path-
way. In addition, CD44v and E-cadherin expression are
maintained or enriched at the invasive front depending on
cancer types [41,42]. However, the function of CD44 in
bladder cancer has not yet been fully clarified. Here, we
identified mir-34a as down-regulated in bladder cancer,
and verified that microRNA-34a functions as an anti-
metastatic microRNA and suppresses angiogenesis in
bladder cancer by directly targeting CD44.
Methods
Patients and samples
In this study, bladder cancer tissue and adjacent normal
tissue specimens were collected from patients who were
diagnosed histopathologically with bladder cancer and
received radical cystectomy in Tongji Hospital, Tongji
Medical College, Huazhong University of Science and
Technology. All the samples were immediately snap fro-
zen and stored in liquid nitrogen (−180°C). To obtain
homogeneous and histological well-characterized samples
for RNA analyses, the nature of the tissue and its specified
composition were determined by an experienced patholo-
gist. The study was approved by the Institutional Review
Board of Huazhong University of Science and Technology,
Tongji Medical College, Tongji Hospital, and written in-
formed consent was obtained from all patients.
Cell culture and transfection
Human bladder cancer cell lines (5637, T24, HT-1376,
J82, SCABER and EJ) were obtained from the American
Type Culture Collection (Manassas, VA), 5637 and T24
were maintained in RPMI-1640 medium; J82 and SCABER
were maintained in DMEM medium; HT1376 was main-
tained in MEM medium; SV-HUC-1 was also purchased
from ATCC and maintained in DMEM/F-12 medium.
Cells were cultured and supplemented with 10% fetal bo-
vine serum (FBS) in a humidified atmosphere of 5% CO2
maintained at 37°C. Six synthetic, chemically modified
short single or double stranded RNA oligonucleotides
(miR-34a mimics, mimics NC, miR-34a inhibitor, inhibitor
NC, agomir-miR-34a and agomir-NC) were purchasedfrom Ribo Biotech (Guangzhou, China). Agomir-miRNA
is a chemically modified miRNA mimics conjugated with
cholesterol. Prevalidated siRNA specific for CD44 and a
nonsilencing siRNA control were purchased from Gene-
pharma Biotech (Shanghai, China). Lenti-miR-34a and
Lenti-NC were purchased from Genechem Biotech
(Shanghai, China). Primary antibody CD44 (1:1000) and
GAPDH (1:10000) were purchased from Sigma-Aldrich,
St. Louis, MO. Oligonucleotide and plasmid transfection
was made by using X-treme GENE siRNA Transfection
Reagent (Roche) and FuGene HD Transfection Reagent
(Roche) respectively, according to the manufacturers’
protocol. The lentivirus mediating the overexpression of
miR-34a and the control vector were supplied by JIKAI
Company Shanghai China. Three days after infection,
puromycin was added to the media at 2 μg/ml, and cell
populations were selected for 2 weeks. Bladder cancer cell
line 5637 and T24 were infected at an MOI of 10–20 and
harvested 48–72 h post-infection.
RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted from bladder cancer cell using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s protocol. The RNA integrity
was evaluated by Nano Drop ND-1000 spectrophotom-
eter. Total RNA was extracted from bladder cancer cell
using TRIzol reagent (Invitrogen Life Technologies) and
then reverse-transcribed using Fermentas RT reagent Kit
(Perfect Real Time) according to the manufacturer’s in-
structions. CD44 expression in bladder cancer cell was
measured by qPCR using SYBR Premix Ex Taq on
MX3000 instrument. 2 μg of total RNA was converted
to cDNA according to the manufacturer’s protocol. PCR
was performed in a total reaction volume of 25.0 μl, in-
cluding 10 μl SYBR Premix Ex Taq(2x), 1 μl of PCR For-
ward Primer (10 μM), 1 μl of PCR Reverse Primer (10
μM), 0.5 μl ROX Reference Dye II(50x)*3, 2 μl of cDNA,
8 μl of double-distilled water. The quantitative real-time
PCR reaction was set at an initial denaturation step of
10 min at 95°C; and 95°C (5 seconds), 63°C (30 seconds),
72°C (30 seconds) in a total 40 cycles with a final exten-
sion step at 72°C for 5 min. All experiments were done
in triplicate. All samples were normalized to GAPDH.
Mir-34a expression in bladder cancer was measured by
qPCR using SYBR Premix Ex Taq on MX3000 instru-
ment. 2 ug of total RNA was converted to cDNA ac-
cording to the manufacturer’s protocol. PCR was
performed in a total reaction volume of 20.0 μl, includ-
ing 9 μl SYBR Premix Ex Taq(2x), 2 μl of PCR Forward
Primer (10 μM), 2 ul of PCR Reverse Primer (10 μM),
0.5 μl ROX Reference Dye II(50x)*3, 2 μl of cDNA, 5 μl
of double-distilled water. The quantitative real-time PCR
reaction was set at an initial denaturation step of 10 min
at 95°C; and 95°C (5 seconds), 60°C (20 seconds), 72°C
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at 72°C for 5 min. All experiments were done in triplicate.
All samples were normalized to U6. The median in each
triplicate was used to calculate relative CD44/mir-34a con-
centrations (ΔCt = Ct median CD44/mir-34a-Ct median
GAPDH/U6). Expression fold changes were calculated
using 2-ΔΔCt methods. The CD44/mir-34a expression dif-
ferences between cancer and control were analyzed using
Student’s t test within SPSS (Version 17.0 SPSS Inc.). A
value of p < 0.05 was considered as statistically significant.
Transwell assay
Migration and invasion assays were performed as de-
scribed as follows, bladder cancer cell lines 5637 and
T24 were transfected with pre-miR-NC and has-miR-
34a mimics for 48h. Transwell inserts that have 6.5-mm
polycarbonate membranes with pores 8.0 μm in size
(Corning, New York, NY, and USA). Matrigel invasion
assay was done using membranes coated with Matrigel
matrix (BD Science, Sparks, MD, USA). A density about
1 × 10^5 of 5637 cells or 1 × 10^4 of T24 was suspended
and then seeded in the upper chambers of 24-well transwell
plates with FBS-free medium. Culture medium containing
10% fetal bovine serum was deposited in the lower cham-
bers. After 12–18 hours cells that migrated were stained by
0.5% crystal violet solution for 15 min and counted. For
invasion, transwell membranes were prepared with matrigel
for plating infected cells. After 24 hours cells that migrated
were stained by 0.5% crystal violet solution for 15 min and
counted. Each experiment was performed in duplicate.Western blot
Briefly, protein was extracted from cells, Protein extraction
with NP40 and were separated on 10% SDS-PAGE gel and
then transferred to PVDF membranes (Bio-Rad). Nonspe-
cific binding was blocked by incubating the PVDF mem-
branes with 5% nonfat milk containing 0.1% Tween-20
and then for 2 hours at room temperature. The membrane
was incubated Primary antibodies included CD44 (1:1000
dilution; Abcam), E-cadherin,vimentin, N-cadherin, beta-
catenin and GAPDH (1:2000 dilution; Cell Signaling Tech-
nology) in TBST +5% nonfat milk at 4°C overnight. After
washing with TBST, the PVDF membranes were incubated
with horseradish peroxidase-conjugated sheep anti-mouse
IgG(1:4,000) for 1 hr at 37°C. At last the proteins were
visualized using ECL-plus detection system (Pierce).
Experimental lung and liver metastasis model
The anti-metastatic activity of miR-34a was tested in
nude mice T24 lung metastasis model as described pre-
viously [25]. T24 cell was stably infected with Lenti-
miR-34a or Lenti-NC containing GFP label. Treated cells
(2 × 106) were suspended in 100 μL of PBS and injectedintravenously via the tail vein. Mice were sacrificed and
lungs were resected 30 days later after injection. The in-
cidence and volume of metastases were estimated by im-
aging of mice for bioluminescence using the Living
Image software (Xenogen, Baltimore, MD). The photon
emission level was used to assess the relative tumor burden
in the mice lungs. Besides that, the mice were killed, their
livers were dissected, and tumor nodules were counted
under a stereomicroscope (Olympus). Nude mice were ma-
nipulated and cared according to NIH Animal Care and
Use Committee guidelines in the Experiment Animal Cen-
ter of the Tongji medical collage of Huazhong University of
science and technology (Wuhan, Hubei, Province, P.R.C.)
In vitro tube formation assay
HUVECs were maintained in endothelial basic medium
containing 2% FBS and 1% penicillin/streptomycin or
the indicated conditioned media (CM) of 5637 and T24
cells. HUVECs (3 × 10^4) were seeded into a 96-well cul-
ture plate pre-coated with Matrigel (BD Biosciences)
overnight and then cultured in the indicated condition.
After 4–6 h incubation, the formation of tubes was
photographed with a phase contrast microscopy (100×
magnification, Olympus Instruments, Inc.), and quanti-
fied by counting branch points in five randomly selected
microscope fields per well. The experiments were con-
ducted twice.
Dual luciferase assay
To verify the precise target of miRNAs, dual luciferase
assays were carried out in both 5637 and T24 cells. Cells
(1 × 10^5) were plated in 12-well plates, 24 h before
transfection. 50 nmoles of miR-34a mimics/inhibitor or
adjacent negative control and 50 ng pmirGLO-30-UTR
vector were co-transfected into cells using X-treme
GENE transfection reagent (Roche Applied Science).
Renilla and firefly luciferase activities were measured
with the Dual-Luciferase Reporter system (Promega) 24
hours after transfection. Firefly luciferase activity was
normalized to Renilla luciferase expression for each sam-
ple. Each experiment was performed in triplicate.
Statistical analysis
Data from all experiments were presented as means ±
s.e.m. from at least three independent experiments and
analyzed by Student’s t-test unless otherwise specified
(Pearson’s correlation). The miR-34a expression was an-
alyzed by Mann–Whitney test, Wilcoxon matched pairs
test for paired data. The correlation between miR-34a
level and CD44 protein expression was calculated by
Spearman’s correlation. The correlation between miR-
34a level in bloodstream and tissues was also calculated
by Spearman’s correlation. P-value < 0.05 was considered
as statistically significant.
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Mir-34a expression’s loss in human bladder cancer and
circulating mir-34a level was reduced in human bladder
cancer
To investigate the role of miR-34a in bladder cancer, we
firstly evaluated the expression of miR-34a in five bladderFigure 1 mir-34a was downregulated in bladder cancer and circulatin
expression of mir-34a expression levels were evaluated by qPCR in bladder ca
expression of circulating mir-34a expression levels were evaluated by qPCR in
C, The expression of mir-34a in blood stream positively correlates with the exp
D, relative expression of CD44 expression levels were evaluated by qPCR in bla
was detected by qPCR. E, MiR-34a inversely correlates with CD44 expression (R
CD44v6 expression levels were evaluated by qPCR in bladder carcinoma cell lin
bladder cancer tissues. Data are plotted as the mean ± SEM of 3 independentcarcinoma cell lines (5637, T24, HT-1376, J82, SCABER
and EJ) and a non-tumorigenic bladder cell line SV-
HUC-1 by qPCR. Compared with SV-HUC-1 cells,
these six bladder carcinoma cell lines had a significantly
lower level of miR-34a expression, meanwhile, we eval-
uated the expression of miR-34a in bladder tissues, andgmiR-34a levels are reduced in bladder cancer. A, relative
ncer.U6 small nuclear RNA was used as an internal control. B, relative
bladder cancer. U6 small nuclear RNA was used as an internal control.
ression in bladder tissues (R2 = 0.3036 P = 0.0411, Pearson’s correlation).
dder carcinoma cell lines. C, miR-34a expression after mimics transcription
2 = 0.5988 P = 0.0412, Pearson’s correlation). F, relative expression of
es. G, CD44v expression pattern in human bladder cancer cell lines and
experiments. **, P < 0.01.
Figure 2 Overexpression of mir-34a inhibits bladder cancer cell invasion and migration and tube formation. A, migration and invasion assay for
renal cancer cells. Representative photographs were taken at × 200 magnification. B, number of migrated and invaded cells were quantified in 4 random
images from each treatment group. Results are the mean± SEM from 2 independent experiments plotted as percent (%) migrating and invading cells
relative to NC treatment. C, representative bioluminescent images of lungs in nude mice at the 30th days after IV injection. D, quantification analysis of
fluorescence signal from captured bioluminescence images. E, Tube formation of HUVECs was determined by assaying the numbers of branch nodes after 6
h of culture under a phase contrast microscope. F, number of branch point was quantified. HUVECs were cultured in the following media: Culture Media of
5637 and T24 cells transfected with mir-34a and NC. G, metastatic nodules in the liver. H, number of nodules was quantified. I, EMT related proteins and VEGF
were determined by immunoblot analysis. J, the density of blots was quantified to show the expression level of EMT related proteins and VEGF, GAPDH was
used as control. NC, Negative Control. *, P < 0.05; **, P < 0.01.
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tissues, compared with the corresponding adjacent con-
trol, (Figure 1A, P < 0.01). Besides that, we evaluated
the expression of CD44 in bladder cancer cell lines and
found the expression of CD44 was up-regulated in
these cell lines (Figure 1D, p < 0.01), suggesting a nega-
tive correlation between the expression of CD44 and
miR-34a in bladder cancer cell lines, which was shown
in Figure 1E (R2 = 0.5988 p = 0.0412). Additionally, we
found that significantly reduced expression of circulat-
ing mir-34a in bladder cancer (Figure 1B, p < 0.01), and
next, we compared the expression of mir-34a in bladder
cancer tissues and bloodstream, showing a positive cor-
relation between them (Figure 1C, R2 = 0.3036 p =
0.0411). Moreover, the data of CD44v expression pat-
tern in human bladder cancer cell lines and bladder
cancer tissues were shown in Figure 1F and Figure 1G.
All the results above indicated that mir-34a takes a
great role in the recurrence and progression in bladder
cancer and this may have future application as part of a
biomarker profile in bladder cancer.
Mir-34a overexpression inhibits bladder cancer cell
invasion and metastasis by modulating EMT related
proteins in vivo and vitro
To assess changes in cell migration, 5637 and T24 cells
transfected with hsa-miR-34a mimics or FAM-labeled pre-
miR-NC (negative control) were allowed to migrate
through a transwell membrane into complete media.
Compared with the negative control, mir-34a overexpres-
sion led to 55% and 65% reduction of migratory cells in
5637 and T24, respectively (Figure 2A).Then to evaluate
cell invasion capability, hsa-miR-34a transfected 5637 and
T24 cells were plated on the membrane which precoated
with matrigel. As shown in Figure 2A, mir-34a overex-
pression significantly reduced 5637 and T24 cell invasion
by approximately 32% and 56%. In intravenous injection
assay, bioluminescence imaging revealed that fluorescence
signal in lenti-mir-34a group were significantly weaker
than lenti-NC group, which mean that less metastasis is
formed in lung after mir-34a overexpression (Figure 2C).
We also found that the number of metastatic nodules in
the liver was dramatically decreased in miR-34a groups
compared with negative controls (Figure 2G). Tumor cells
stably infected with miR-34a lentivirus established signifi-
cantly fewer metastatic colonies (Figure 3B). E-cadherin,
β-catenin and Vimentin were also detected with immuno-
fluorescence in 5637 cells. Result shown that miR-34a
overexpression increased E-cadherin expression but de-
creased β-catenin and Vimentin expression (Figure 3C).
Moreover, EMT-related genes like N-Cadherin, E-
Cadherin, Vimentin and Beta-catenin were also examined
by immunoblot and qPCR assay after mir-34a restoration.
Result indicated that miR-34a could promote E-cadherinand inhibited N-cadherin, Beta-catenin and Vimentin
mRNA in all these cell lines. Immunoblot showed that
miR-34a consistently promoted E-cadherin protein ex-
pression and inhibited N-cadherin, Beta-catenin and
Vimentin protein expression in all these cell lines. These
results suggested that miR-34a could inhibit EMT in blad-
der cancer cell (Figure 2I, Figure 2J and Figure 4A). Some
kinds of EMT-driving transcription factors are responsible
for EMT phenomenon in this research article (Figure 4G).
The data indicated that miR-34a functions as a tumor sup-
pressor in bladder cancer.Mir-34a suppressed the angiogenesis of bladder cancer
cells in vivo and vitro
Some previous studies indicate that CD44 promotes the
invasion and angiogenesis of tumor cells [25,28]; we fur-
ther investigated the effects of miR-34a overexpression
and CD44 restoration on cultured bladder cancer cells.
Western blotting indicated that transfection of CD44
rescued the miR-34a–induced downregulation of CD44
(Figure 4B). The tube formation of endothelial cells was
suppressed by treatment with the medium precondi-
tioned by stable transfection of bladder cancer cells with
miR-34a precursor (Figure 2E). We next investigated the
efficacy of miR-34a against angiogenesis in vivo. In the
xenograft tumors, the VEGF and CD44 were also reduced
by stable transfection of miR-34a precursor (Figure 3A).
Moreover, stable transfection of miR-34a precursor re-
sulted in a decrease in CD31-positive mean vessel density
within tumors (Figure 3A). These results indicated that
miR-34a remarkably decreased the angiogenesis of bladder
cancer cells in vivo and vitro.Knockdown of CD44 suppressed the migration, invasion
and angiogenesis of bladder cancer cells
Because above results indicated the negative regulation
of CD44 expression by miR-34a, we hypothesized that
knockdown of CD44 should have a similar effect on cul-
tured bladder cancer cells. To this end, 5637 and T24
cells were infected with lentiviral constructs containing
siRNA against CD44 or the negative control (Figure 4B).
Remarkably, silencing of CD44 inhibited 5637 and T24
cells angiogenesis (Figure 4C), migration and invasion
(Figure 5A). These results were consistent with the find-
ings that overexpression of mir-34a suppressed the
angiogenesis, migration and invasion of bladder cancer
cells in vitro, providing further evidence that CD44 was
involved in mir-34ameiated suppression of bladder can-
cer cells. Accordingly, identification of CD44 as a miR-
34a target gene may explain, at least in part, why overex-
pression of miR-34a suppressed the migration, invasion,
and angiogenesis of bladder cancer cells.
Figure 3 Overexpression of miR-34a attenuated the metastasis and angiogenesis of bladder cancer in vivo. A, hematoxylin/eosin (HE)
and immunohistochemical staining revealed that stable transfection of miR-34a precursor resulted in decreased expression of VEGF, CD44 and
CD31 within tumors. The mean vessel density within tumors decreased after stable overexpression of miR-34a. B, T24 cells were injected into the
tail vein of nude mice (5 × 106cells per mouse). Tumor cells stably infected with miR-34a lentivirus established significantly fewer metastatic
colonies. C, Representative photographs of immunofluorescence were taken at × 400 magnification.
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interacted with a putative binding site in the CD44 3’UTR
To investigate the hypothesis that miR-34a may influence
the CD44 expression in bladder cancer, combination with
the previous reports, computational prediction was done
by miRNA databases. In the CD44 3’-UTR, there was one
potential binding site of miR-34a with high complemen-
tarity (Figure 6F), the miR-34a- binding site was located at
bases 1855–1878 and 3399–3422 of the CD44 3’-UTR, re-
spectively (Figure 6F). Next, we investigated the direct ef-
fects of miR-34a on CD44 expression in bladder cancer
cell lines; we conducted the miRNA overexpression exper-
iments. Overexpression of miR-34a precursor into bladder
cells resulted in increase of miR-34a levels (Figure 6A-D).
Then western blotting, showed that stable transfection of
miR-34a precursor resulted in decreased protein levels of
CD44 in bladder cancer cells, when compared with nega-
tive control (Figure 6E). To determine whether miR-34a
could repress CD44 expression or not by targeting its
binding sites in the CD44 3’-UTR, the PCR products con-
taining intact target sites or a mutation of miR-34a seed
recognition sequence (Figure 6F) were inserted into the
luciferase reporter vector. The plasmids were transfectedinto bladder cancer cells stably transfected with empty
vector or miR-34a precursor. The luciferase activity nor-
malized to that of firefly was significantly reduced in the
tumor cells stably transfected with miR-34a precursor
(Figure 6G), and the effect was abolished by mutating the
putative miR-34a–binding site within the 3’-UTR of CD44
(Figure 6G). Moreover, knockdown of miR-34a with anti-
miR-34a inhibitor increased the luciferase activity in 5637
and T24 cells (Figure 6G), whereas mutation of miR-34a
recognition site abolished these effects (Figure 6G). These
results indicated that miR-34a directly and specifically
interacted with the target site in the CD44’-UTR.
MiR-34a function as an anti-metastatic microRNA via
directly targeting CD44 in bladder cancer
CD44 was overexpressed in bladder cancer and had a cen-
tral role in regulating diverse aspects of bladder cancer
pathogenesis. Interestingly, as predicated by TargetScan
and previous study, miR-34a could negatively regulate dif-
ferent kinds of mRNAs including CD44 in some human
cancers. Restoration of miR-34a could markedly decrease
CD44 protein (Figure 6E). According to the previous
study in prostate cancer [30] dual luciferase reporter assay
Figure 4 mir-34a targets CD44 in bladder cancer cells and the validation of transfection/infection. A and B, mir-34a expression was
detected by qPCR after infection of miR-34a lentivirus and corresponding negative control in 5637 and T24 for 4 days. C and D, mir-34a
expression was detected by qPCR after infection of miR-34a mimics or inhibitor and corresponding negative control in 5637 and T24 for 48
hours. CD44 protein expression was inhibited in miR-34a transfected bladder carcinoma cells. E, CD44 expression was detected by western blot
after overexpression of miR-34a and corresponding negative control i 5637 and T24. F and G, The seed regions of the miR-34a target sites in
CD44 and the luciferase activity assay. *, P < 0.05; **, P < 0.01.
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of miR-34a in bladder cancer cells (Figure 6G). To con-
firm the synergistic effect of CD44 and miR-34a in
tumorigenesis, we pulled down the expression of CD44
by specific siRNA resulting in decreased capability of
cell angiogenesis, invasion and migration (Figure 4C
and Figure 5A), which is in parallel with miR-34a overex-
pression in all the bladder cancer cell lines. Subsequently,
we proved that restoration of CD44 could rescue theantitumor effects of miR-34a by co-transfection of miR-
34a mimics and CD44 in bladder cancer cell lines
(Figure 4E and Figure 5B). All data presented here strongly
support our hypothesis that the tumor-suppressive effect
of miR-34a is mediated by directly targeting CD44.
Discussion
Over the past decade, the dysregulation of miRNAs con-
tributed to the pathogenesis of most human cancers,
Figure 5 The anti-angiogenesis functions of miR-34a were mediated by reducing the production of CD44. Knockdown of CD44 by siRNA
inhibits tube-formation and increased CD44 expression could efficiently reverse the effect of anti-angiogenesis of miR-34a in bladder cancer cells
A, EMT related factors and VEGF was detected by qPCR. Data are plotted as the mean ± SEM of 3 independent experiments. B, western blotting
indicated that transfection of si-CD44, into 5637 and T24 cells resulted in decreased CD44 expression when compared with negative control.
Western blotting indicated that transfection of CD44 restored the downregulation of CD44 induced by stable miR-34a overexpression. C and D,
the tube formation of endothelial HUVEC cells was suppressed by treatment with the medium preconditioned by CD44-knockdown 5637 and
T24 cells, when compared with that of control cells. E and F, increased CD44 expression could efficiently reverse the effect of anti-angiogenesis
of miR-34a in bladder cancer cells. *, P < 0.05; **, P < 0.01. G, exchange of EMT-driving transcription factors, LEF1 and Axin-2 in T24/5637-mir-34s.
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acting as activators or suppressors of metastasis and
angiogenesis [43]. In our study, we identified a crucial
tumor-suppressive miRNA, mir-34a, which plays an im-
portant role in the progression in bladder cancer. Some
important prior studies including ours have reported on
the dysregulation of various miRNAs including mir-34a
in bladder cancer [22,25,27]. Although there are many
related research, that microRNA-34a functions as ananti-metastatic microRNA and suppresses angiogenesis
in bladder cancer by directly targeting CD44 still need
further illuminated. Besides, although several other stud-
ies have investigated circulating miRNAs, they demon-
strated that mir-34a plays a key role in NAFLD and
colorectal cancer pathogenesis is supported by the evi-
dence that serum levels of circulating mir-34a increased
in participants with NAFLD and colorectal cancer, and
they put forward that mir-34a may present a therapeutic
Figure 6 The anti-metastatic functions of miR-34a were mediated by reducing the production of CD44. Knockdown of CD44 by siRNA
inhibits bladder cancer migration and invasion. Increased CD44 expression could efficiently reverse the effect of anti-metastatic of miR-34a in
bladder cancer cells. A, matrigel invasion assay indicated the decreased invasion capabilities of CD44-knockdown 5637 and T24 cells than those
of control cells. B, Transfection of CD44 rescued the angiogenic capabilities of miR-34a-overexpressing cells. *, P < 0.05; **, P < 0.01.
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a novel biomarker to predict NAFLD and colorectal can-
cer susceptibility and progression [44,45]. There have
few reports on the expression of circulating mir-34a in
bladder cancer, and the level of miR-34a was correlated
with the level of mir-34a in bladder cancer tissues. An in-
teresting study has suggested that a panel of miRNAs may
have greater sensitivity and specificity than use of any single
miRNA in identifying diseases [46,47]. Now, they alert us
that it is possible that miR-34acombined with another
miRNA, mRNAs or LncRNAs as part of a “biomarker
panel” may together provide sufficient sensitivity and speci-
ficity to distinguish bladder cancer cases from controls and
from other types of malignancies. Although further work
needs to be done in order to clarify this, our next work will
focus on this subject. These data indicated that the circulat-
ing level of mir-34a is proportionately associated with
bladder cancer mir34a expression and circulating miR-
NAs may be able to be used as biomarker for bladder
cancer.
Mir-34a has been reported taken great part in the oc-
currence and development of some human cancer con-
tains bladder cancer [25], prostate cancer [30], cervical
carcinoma [48], renal cancer [49] by targeting certaintargets. And previous studies reported that upregulated
the expression of miR-34a could exchange the expression
of beta-catenin [41,50]. Our studies focus on it that
microRNA-34a functions as an anti-metastatic microRNA
and suppresses angiogenesis in bladder cancer by directly
targeting CD44 could further enrich the theory of biology.
Here, on the basis of our functional tests, findings that
miR-34a was frequently downregulated in bladder cancer
tissues and that miR-34a could suppress cell migration
and invasion, and suppress tubefomation. Our data in vivo
suggested that altered expression of miR-34a played a role
in bladder cancer cellular metastasis and angiogenesis. In
the subsequent mechanism research, mir-34a has many
different certain targets in regulating different kinds of hu-
man cancer. CD44 overexpression eliminated the pro-
apoptotic effects of miR-34a which is similar to what’s ob-
served in medulloblastoma [51]. CD44 has been identified
to be the direct target of miR-34a in prostate cancer, blad-
der cancer and renal cancer [25,28,30]. These results sug-
gest that the role of miR-34a is possibly tumor-specific and
highly dependent on its targets in different cancer cells.
Our study proved that mir-34a functions as an anti-
metastatic microRNA and suppresses angiogenesis by dir-
ectly targeting CD44 in bladder cancer and subsequently
Yu et al. Journal of Experimental & Clinical Cancer Research  (2014) 33:779 Page 12 of 13suppress CD44 that regulates transcription of a variety of
genes in bladder cancer cells.
Conclusions
In summary, our research has demonstrated that miR-34a
is significantly downregulated in bladder cancer tissues
and bloodstream. MiR-34a overexpression can inhibit
bladder cell migration, invasion, tubefomation in vitro and
metastasis and angiogenesis in vivo. Furthermore, CD44 is
a direct and functional target of miR-34a, and the func-
tions that CD44-mediated can be reversed by miR-34a in
bladder cells. This novel miR-34a/CD44/EMT related fac-
tor provides new insight into the mechanisms underlying
tumor metastasis in bladder cancer. Combination with
other pales of new specific biomarkers and restoration of
miR-34a expression may be a potential diagnostic and
therapeutic strategy to assess the prognosis and treatment
of bladder cancer in the future.
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